Philips and Illumina to co-develop integrated genomics solutions for oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Royal Philips and Illumin Inc. announced a strategic collaboration that aims to integrate Illumina’s sequencing systems for large-scale analysis of genetic variation and function and Philips’ IntelliSpace Genomics clinical informatics platform, and to coordinate marketing and sales of the resulting solutions. Philips and Illumina will also seek to engage in clinical research collaborations with health systems in the U.S. that want to develop precision medicine programs in oncology.

Profiling tumors using genomic information is critical for complex cancer cases, and next-generation DNA sequencing—the process of rapidly profiling large sections of the genome in parallel to find mutations—is increasingly being used for this. However, challenges remain in developing ways to rapidly and accurately interpret genomic findings in the context of a patient’s condition.

While cancer patients can have hundreds of gene variants in their tumors, only a small number may actually drive the individual’s specific cancer or may have actionable therapeutic implications for a particular patient. The patient’s history, related lab tests and cancer type are needed for a meaningful interpretation of the genomic data.

Philips and Illumina will collaborate to provide new solutions aimed at the acquisition, analysis, annotation, and interpretation of genomics data in oncology cases. The data will be acquired by Illumina’s BaseSpace Sequence Hub connected to its instruments and will be processed through Philips’ IntelliSpace Genomics solution for oncology. This solution will combine data from multiple sources—radiology, immunohistochemistry, digital pathology, medical records and lab tests—and will deliver a consolidated dashboard view. This system will support researchers to develop insights more efficiently and will ultimately support lowering the cost of health care delivery and improved health outcomes.

The two companies intend to collaborate on system integration, cohort analysis and health economics applications, and future research programs. Laboratories adopting the solution will be able to integrate sequencing data with information from multiple data sources (e.g., imaging, pathology and laboratory). The Illumina-Philips solution will also give them ready access to advanced analytics, deep learning technologies and available reference literature, guidelines, and evidence in a single view.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login